Datasets:

ESGBERT

/

governance_data

like 0

Follow

ESGBERT 25

Risk Management To identify and manage climate-related issues we are integrating climate impact into our existing risk management structure using the Environment, Health & Safety team management system, the CSR materiality assessment, business continuity program management, supply chain risk reviews, and internal audit risk program.

As our enterprise risk management program evolves, we plan to integrate climate as a key component.

In this, our first annual Communication on Progress, we describe our actions to integrate the Global Compact and its principles into our business strategy, culture, and daily operations.

We remain committed to aligning our business practices to the rights, labor, environment, and anti-corruption.

Focus on Integrity GRI 408, 409, 412, 413, 414 2 Businesses should make sure that they are not complicit in human rights abuses.

Focus on Integrity GRI 412, 414 4 Businesses should uphold the elimination of all forms of forced and compulsory labour.

Focus on Integrity elimination of discrimination in respect of employment and occupation.

To provide a consistent basis for measurement and reporting the Company utilizes a third-party data management system.

Criteria The greenhouse gas data was prepared in accordance with the Greenhouse Gas Protocol, a Corporate Accounting and Reporting Standard (revised edition, 2004).

The testing conducted at company facilities across reporting varied based upon the proportion of energy consumption and corresponding emissions relating to Scope 1 and 2.

Testing focused on two facilities which accounted for a significant proportion of the Illumina energy consumption and emissions and were individually material.

We: • Carried out interviews with key personnel to understand the systems and controls in place during the reporting period • Assessed the systems, processes, and controls to collate, aggregate, validate and report the data • Checked the relevant conversion factors and GHG emission calculations • Reviewed any matters showing significant variations from prior years • Reviewed the appropriateness of the GHG emissions and other environmental data provided by Illumina and their third-party data management system service provider • Tested a sample of records against underlying records The relative effectiveness and significance of specific control procedures at Illumina and their effect on assessment of control risk at a facility level are dependent on their interaction with the controls and other factors present at individual facilities.

Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing, and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to manufacture robust instrumentation and consumables; (v) the success of products and services competitive with our own; (vi) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (vii) the impact of recently launched or pre-announced products and services on existing products and services; (viii) our ability to further develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms; (ix) our ability to obtain regulatory clearance for our products from government agencies; (x) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xi) our ability to successfully identify and integrate acquired technologies, products, or businesses; and (xii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms public conference calls, the date and time of which are released beforehand.

We have a duty of care towards patients, communities, our people and the environment.

This report communicates our approach and commitments towards sustainability and corporate social responsibility (CSR).

During focus on environmental, social and governance issues.

I am proud to say that we have maintained our constituency in the FTSEand remain members of the United Nations Global Compact where we are committed to upholding their ten principles centered around human rights, labour, the environment and anti-corruption.

We recognise the value of integrating environmental, social and governance (ESG) considerations into our business.

By acting responsibly and with integrity, we are benefitting the communities in which we operate and supporting the delivery of our business strategy.

Gender equality Hikma celebrates diversity and prides itself on a culture of inclusion.

https://www.hikma.com/about/worldwide/ https://www.hikma.com/about/worldwide/ We are committed to upholding the highest ethical standards in the conduct of our global business operations, which is grounded in our culture of progress and belonging, and powered by our three core values: innovation, collaboration and caring.

Our Code provides guidance to our employees and partners on the ethics of Hikma’s business activities through the identification and discussion of various risks associated with our business.

Hikma employees, officers and directors are trained on the Code of Conduct as part of their induction and are provided refresher training on a periodic basis.

Our Compliance, Responsibility and Ethics Committee (CREC) provides oversight of our global compliance programme and the management of associated risks, including bribery and corruption.

We have a zerotolerance policy for bribery and corruption at Hikma.

We also comply with the UK Bribery Act the US Foreign Corrupt Practices Act, as well as global anti-corruption standards and local antibribery and corruption laws. Operating responsibly and ethically Supporting the freedom of association and collective bargaining We support freedom of association and collective bargaining across Hikma to ensure employees are fairly represented and their rights are protected.

We continue to take steps to improve our anti-modern slavery practices; enhancing due diligence processes for our suppliers and ensuring completed compliance training.

In launched RiskRate, NAVEX Global’s third party risk management platform, enabling us to more effectively monitor and address potential compliance issues with our suppliers.

Our goals for · Increasing the input of third-party details on our RiskRate system to capture all third parties (new and existing) by the end of Q1 2022; · Reviewing and updating the Code of Conduct and training, including modern slavery training, ahead of rolling out annual compliance refresher training for all Hikma employees globally in the summer of 2021; and · Taking proactive steps to consider which parts of Hikma’s business and supply chains may be most at risk, to ensure that such risks can be managed efficiently.

Diversity, equity and belonging Hikma celebrates diversity and prides itself on a culture of inclusion.

During the year, we conducted focus groups and peerto-peer discussions to evaluate opportunities to strengthen our culture of belonging.

demonstrate strong Environmental, Social and Governance (ESG) practices as measured against globally recognised standards.

such as human rights, anti-corruption, environmental performance, health and safety, and community engagement.

to reduce interaction and strengthen social distancing between departments and shifts, and instituted restrictions on travel and in-person meetings in line with public health authority guidelines.

As part of the We Are Hikma campaign, we established webinars and online resources for employees on themes related to mental wellbeing, stress management and general awareness.

When needed in the pre-approval phase, we submit a registration dossier to relevant authorities that includes risk management plans (RMPs) detailing the risk management system proposed to identify, characterise and minimise the safety risks.

Pharmacovigilance is monitored at the highest levels of our business and is included in Globally registered compounds 5,000+ Submissions overseen annually Our commitment to patient safety 21Hikma Pharmaceuticals PLC | Sustainability Report 2020 our enterprise risk management process, which is overseen by the Executive Committee and the Board on a regular basis.

We use a global safety database to support our process for adverse event management and electronic reporting.

This helps ensure that our pharmacovigilance activities remain in compliance with global safety reporting obligations.

In eLearning course, Pharmacovigilance 101, to all Hikma employees through our Learning Management System (LMS).

In addition, the global pharmacovigilance team also launched a new Group Pharmacovigilance Policy taking effect 15 July 2020.

Under this policy, all Hikma employees must report to the PV department any adverse event, adverse drug reaction or other safety report relating to Hikma products as soon as possible, and in all cases not later than one business day.

How we perform To ensure our pharmacovigilance system is achieving its objectives, we monitor our worldwide compliance metrics every month.

Health authority regulatory reporting (aggregate reports) Our pharmacovigilance audit strategy ensures that risk-based audits are performed annually, in line with our pharmacovigilance audit plan.

Our pharmacovigilance audit programme helps ensure our compliance with regulations and provides opportunities to continuously improve our existing systems.

In 2020, we audited 3 affiliates and Corporate PV.

In addition, we underwent a pharmacovigilance regulatory inspection by the Saudi Food and Drug Authority, and one audit from a partner.

the UK government’s policy on Streamlined Energy and Carbon Reporting.

— We quantify and report our organisational GHG emissions in alignment with the World Resources Institute’s Greenhouse Gas Protocol Corporate Accounting and Reporting Standard and in alignment with the Scope 2 Guidance.

Joint ventures with less than 50% holding are not included as we do not have operational control.

This year, we introduced measurements of our environmental impact that derive from various indirect emissions sources (scope 3), including water consumption, water treatment and waste management.

We are aligning our internal processes and public disclosure with the Taskforce on Climate-related Financial Disclosures (TCFD) recommendations.

• Risk Management: how we identify, assess and manage climate-related risks.

Governance To ensure that sustainability topics are considered at the highest level of decisionmaking, they have been placed under the remit of our Compliance Responsibility and Ethics Committee (CREC).

Risk management We assess climate-related risks through our emerging risk management process.

The approach helps to ensure appropriate management attention is provided to this developing area.

Delay in the policy response needed to reduce global emissions.

Several policy changes required to compensate late start.

This verification exercise has been performed to the ISO standard.

Description Of Activities The organisational boundary was established following the operational control approach.

Guidance: An Amendment to the GHG Protocol Corporate Standard ii.

We conducted our verification of the GHG assertion of Hikma, which included assessment of the company GHG information system and monitoring and reporting methodology.

This assessment included the collection of evidence supporting the reported data and multiple checks relative to the provisions of the legislation, reporting standard and calculation methodologies referenced in the verification criteria.

Our examination included assessment, on a limited sample basis, of evidence relevant to the reporting of emission information.

p Principle 3 Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining.

No significant changes during the reporting year 102-12 List of externally-developed economic, environmental and social charters, principles, etc.

In-Accordance Core 102-56 External assurance NA We have developed a GRI index to indicate which elements of the GRI Standards are covered in our reporting.

United Nations Global Compact Principles As I write this, we are in the midst of an unprecedented health crisis—one that has impacted the lives of so many around the world.

practices for complying with laws, regulations and internal procedures.

release hormones that control various functions of the digestive system.

Because biosimilars do not require as many expensive or lengthy clinical trials, they have the potential to lead to faster access to these medicines, more treatment options and greater cost competition.

Teva’s Global Publication Policy defines our position on scientific and medical publications to ensure full transparency and compliance with all applicable external laws, guidelines and requirements, while protecting Teva’s intellectual property.

Amalia Adler-Waxman, Teva’s Vice President of ESG and Global Health, discussed MCC and the National Health Service (NHS) Long-Term Plan, including how integrated care systems and innovation can help patients take control of their well-being.

leader on NCD policy and practice, convener of the civil society movement and an advocate for people at risk of, or living with, NCDs.

or those available legally by prescription that are misused or subsequently diverted—is a public health crisis in the US and other countries around the world.

Contributing to Healthy Communities https://www.tevapharm.com/globalassets/tevapharm-vision-files/https://www.tevapharm.com/globalassets/tevapharm-vision-files/2019-global-patient-advocacy-disclosure.pdf As a global company that affects the health of millions of people, we have an immense responsibility—a responsibility to act ethically and with integrity and maintain accountability throughout our supply chain to ensure our medicines get to those who need them, safely and consistently.

In employees to ensure a healthy and safe workforce, implemented new programs that foster a diverse and inclusive culture and offered educational opportunities to promote growth and development.

We aim to create an empowering culture that recognizes and acknowledges our employees’ accomplishments.

in total lost workdays Teva’s facility in Goa, India was awarded the Safety Excellence Award in Sustainability Awards, which recognize and honor efforts made by companies that actively integrate sustainability principles into their business culture.

It represents knowledge, wisdom and oversight of Teva’s business practices—helping to create accountability for compliance across the business.

Anti-trust training was also included in the Code of Conduct recertification.

Compliance and Ethics Our and transparent behavior across our business, because compliance is everyone’s responsibility.

of Conduct breaches to our Office of Business Integrity.

as outlined in our Policy on Clinical Trial Transparency & Disclosure.

we implement measures to avoid, reduce or control pollution and promote responsible and efficient use of energy and natural resources across our company and supply chain.

of light and heat passing through the windows, which reduces energy consumption during summer — Has two stratified tanks that allow recovery of energy for cooling and heating systems — Uses 33 Teva 2019 ESG Progress Report | Leading a Responsible Business https://letstalkrespiratory.com/about-teva/ Teva’s EHS Excellence Awards recognize initiatives across the company that drive sustained improvements in EHS systems, processes or performance and promote a safe and responsible culture.

In Nigeria, Teva supported a government to government capacity building seminar on patient safety and anticounterfeiting for senior staff of the Nigerian National Agency for Food and Drug Administration Control (NAFDAC), organized by the Israeli Embassy.

We hold each of our partners to the same standards we hold ourselves to and expect them to conduct business ethically, act with integrity and protect human rights.

and incorporates PSCI Principles into our Supplier Code of Conduct.

to healthy communities and lead a responsible business.

in relation to the information set out below and presented in Teva’s and Governance Progress Report (‘the Report’).

view of Teva’s materiality assessment process, in accordance with the stated reporting criteria.

— Interviews with management representatives responsible for preparing the content and leading the material topic areas and with relevant personnel to understand and evaluate the materiality assessment and processes used for determining and reporting the selected topics.

Scope of our assurance engagement Whether the Stakeholder Engagement’ section of the report presents, in all material respects, a complete and balanced view of Teva’s materiality assessment process in accordance with the reporting criteria.

Our conclusions Based on our activities, as described below, nothing has come to our attention to indicate that the the ‘Materiality Assessment and Stakeholder Engagement’ section of the Report does not present, in all material respects, a complete and balanced view of TEVA’s materiality assessment process, in accordance with the stated reporting criteria.

A review of external media reporting relating to TEVA to identify relevant sustainability issues in the reporting period.

Interviews with management representatives responsible for preparing the content and leading the material topic areas and with relevant personnel to understand and evaluate the materiality assessment and processes used for determining and reporting the selected topics.

Jennifer Iansen-Rogers Head of Corporate Assurance ERM Certification and Verification Services, London www.ermcvs.com Email: [email protected] ERM CVS is a member of the ERM Group.

Composition of the highest governance body and its committees Proxy Statement for Teva's 2020 Annual Shareholder Meeting, page 15 for information on director independence, executive/non-executive, age, tenure and gender; pages 8-13 for other significant positions and commitments and qualifications for service; page 16 for competencies 102-23 Chair of the highest governance body Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, page 17; Teva's non-executive chairman of the board is Dr. Sol Barer.

102-37 Stakeholders’ involvement in remuneration Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, pages 26-27, "Shareholder Engagement"; voting results for 2019 102-38 Annual total compensation ratio Proxy Statement for Teva’s 2020 Annual Shareholder Meeting, page 71 102-40 List of stakeholder groups 2019 ESG Progress Report, page 51 102-41 Collective bargaining agreements We respect the right of our employees to organize or join associations, and bargain collectively, if they choose to do so.